After Dust Up Over Emflaza's Price, Ubl Says PhRMA-Member Review Should Be Done In Matter Of Weeks

Pharmaceutical Research and Manufacturers of America should be done reviewing membership criteria in a matter of weeks, according to PhRMA President and CEO Stephen Ubl, who said PhRMA members should be investing heavily in drugs that are new, different and valuable to patients. The trade group announced this month it is reviewing that criteria following criticism of PhRMA member Marathon Pharma for setting an $89,000 annual price for the muscular dystrophy drug Emflaza (deflazacort) that patients had been importing at...